How does one manage patients with rheumatoid arthritis and positive serology to hepatitis B, hepatitis C, human immunodeficiency virus?;¿Cómo manejar al paciente con artritis reumatoide y serología virus de hepatitis B, hepatitis C, virus de la inmunodeficiencia humana?

Reumatologia Clinica

Volumn 7, Issue 3, 2011, Pages 203-207

  Cabrera Villalba, Sonia Raquel ^a   Victoria Hernández Miguel, María ^a   Sanmartí Sala, Raimon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

HIV; Rheumatoid arthritis; Viral hepatitis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERFERON; LEFLUNOMIDE; METHOTREXATE; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG-INDUCED LIVER INJURY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953771671     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.11.013     Document Type: Article

References (15)

1. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008, 6:1315-1341.
2. Calabrese L.H., Zein N.N., Vassilopoulos D. Hepatits B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006, 65:983-989.
3. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect Dis. 2002, 2:479-486.
4. Ibañez Bosch R. Tratamiento de situaciones clínicas difíciles en pacientes que presentan artritis reumatoide con hepatitis. Reumatol Clin. 2009, 5(S1):53-60.
5. Flowers M.A., Heathcote J., Wanless I.R., Sherman M., Reynolds W.J., Cameron R.G., et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med. 1990, 112:381-382.
6. Ito S., Nakazono K., Murasawa A., Mita Y., Hata K., Saito N., et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001, 44:339-342.
7. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005, 4:599-608.
8. De la Monte S.M., Hutchins G.M., Moore G.W. Risk factors for development of lethal sequelae after hepatitis B virus infection in humans. Am J Med. 1984, 77:482-488.
9. Ramos-Casals M. Manifestaciones extrahepáticas en pacientes con infección crónica por el virus de la hepatitis C. Reumatol Clin. 2009, 5:71-75.
10. Calabrese L.H., Zein N., Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004, 63(Suppl 2):ii18-ii24.
11. Dewan Manahan T., Hooker R., Maher L., Brown G., Reimold A. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. JCR. 2010, 16:332-334.
12. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., Reveille J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008, 67:710-712.
13. Tornero Molina J., Sanmartí Sala R., Rodríguez Valverde V., Martín Mola E., Marenco de la Fuente J.L., González Álvaro I., et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2010, 6:23-36.
14. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008, 59:762-784.
15. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010, 69(Suppl 1):i2-i29.